menu
    • menu
    [{"orgOrder":0,"company":"Bioasis","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend-peptide","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioasis","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Bioasis \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"Bioasis \/ Chiesi Group"},{"orgOrder":0,"company":"Bioasis","sponsor":"Oxyrane","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Enzyme Replacement Therapies","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioasis \/ Oxyrane","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Oxyrane"},{"orgOrder":0,"company":"Bioasis","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bioasis \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Janssen"},{"orgOrder":0,"company":"Bioasis","sponsor":"Neuramedy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Tomaralimab","moa":"TLR2","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bioasis \/ Bioasis","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Bioasis"},{"orgOrder":0,"company":"Bioasis","sponsor":"Cresence","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NORWAY","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"CRES101","moa":"M2 polarization","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Bioasis \/ Bioasis","highestDevelopmentStatusID":"5","companyTruncated":"Bioasis \/ Bioasis"},{"orgOrder":0,"company":"Bioasis","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bioasis \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Midatech Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioasis

    Menu

    Bioasis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Midatech Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc

                            Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Midatech Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRES101

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Recipient : Cresence

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

                            Details : Under the terms of the agreement, the Company purchased all right, title and interest in the intellectual property owned by the Sellers related to their epidermal growth factor (EGF) platform, including CRES101.

                            Brand Name : CRES101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 16, 2022

                            Lead Product(s) : CRES101

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Recipient : Cresence

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomaralimab

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Neuramedy

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

                            Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.

                            Brand Name : NM-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : Tomaralimab

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Neuramedy

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bioasis Enters Into Research Collaboration With Janssen

                            Details : Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis’ xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 11, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzyme Replacement Therapies

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Oxyrane

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

                            Details : Oxyrane is developing enhanced enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs) using a proprietary, glyco-engineered yeast expression system for efficient targeting of enzymes to the lysosome.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Enzyme Replacement Therapies

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Oxyrane

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bioasis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Transcend-peptide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : CHIESI USA INC

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

                            Details : The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.

                            Brand Name : xB3

                            Molecule Type : Peptide

                            Upfront Cash : $3.0 million

                            June 29, 2020

                            Lead Product(s) : Transcend-peptide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : CHIESI USA INC

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth